Research Nester’s recent market research analysis on “Mometasone Market: Global Demand Analysis & Opportunity Outlook 2036” delivers a detailed competitors analysis and a detailed overview of the global Mometasone market in terms of market segmentation by dosage form, indication, route of administration, distribution channel, and by region.
Increased Product Launches by Key Players to Promote Global Market Share of Mometasone
The global mometasone market is expected to grow over the forecast period because of a rise in product launches and market player approvals. For example, the European Commission (EC) approved Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide, and mometasone furoate [IND/GLY/MF]) in 2020 to treat adult patients with asthma who have not had their asthma adequately controlled with a maintenance regimen that includes a high-dose inhaled corticosteroid (ICS) and a long-acting beta2 agonist (LABA) and who have experienced one or more asthma exacerbations in the year prior. This was announced by Novartis in July 2020.
Some of the major growth factors and challenges that are associated with the growth of the global Mometasone market are:
Growth Drivers:
Surge in the Cases of Respiratory AllergiesGrowing Investment in Research and Development ActivitiesChallenges:
Mometasone side effects include headaches, nausea, vomiting, lack of appetite, and allergic reactions. However, some severe adverse effects, such as crusting, blurred or lost vision, and white spots in the mouth or nose, might have a detrimental effect on the market's growth. As a result, the market for mometasone may experience negative growth because of the significant side effects.
Some other factors such as the growing use of substitutes and strict regulations by governments in various nations may hinder the growth of the mometasone market.
Access our detailed report at: https://www.researchnester.com/reports/mometasone-furoate-market/5507
By indication, the global Mometasone market is segmented into diabetes, inflammatory skin disorders, asthma, and allergic rhinitis. The allergic rhinitis segment is poised to hold the largest share of 45% by the end of 2036. It is anticipated that as healthcare prices rise, so will the need for faster and better diagnostic methods. For businesses operating in the global market for the treatment of chronic allergic rhinitis, this will offer enormous potential opportunities. Apart from the substantial financial strain that respiratory diseases cause to society because of their early mortality and incapacity, they also increase the cost of prescription drugs, medical care, and indirect expenses related to lost productivity. Perennial allergic rhinitis frequently necessitates treatment in addition to allergy asthma. Globally, allergic rhinitis is also affecting the market for therapies for the condition. Furthermore, mometasone nasal spray is often prescribed to assist lessen the symptoms of allergic rhinitis. This market segment's growth can be ascribed to mometasone's
By region, the North America Mometasone market is to hold the largest share of 34% during the projected period. The increase might be ascribed to the major firms in the area launching an increasing number of psoriasis awareness programs. The high frequency of skin diseases like psoriasis and eczema in the region is also driving market expansion. For example, 7.5 million people in North America experience psoriasis annually. Additionally, skincare and dermatological health are growing in popularity in North America, which has increased demand for products like mometasone. The quick developments in medical research and technology have also made it feasible to create new and enhanced mometasone formulations. As a result, each of these elements is assisting in the region's mometasone market expansion.
This report also provides the existing competitive scenario of some of the key players of the global Mometasone market which includes company profiling of Perrigo Company plc, Bausch Health Companies Inc., Glenmark Pharmaceuticals Limited, Vetoquinol USA, AstraZeneca plc, Intersect ENT, Kyorin Remedio Co., Ltd, Teikoku Seiyaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, and others.
Sign in to leave a comment.